Daclatasvir plus Asunaprevir: First Global Approval

被引：46
作者：
Poole, Raewyn M. [1 ]
机构：
[1] Springer, Auckland 0754, New Zealand
来源：
DRUGS | 2014年 / 74卷 / 13期
关键词：
CHRONIC HEPATITIS-C; DIRECT-ACTING ANTIVIRALS; INTERFERON-FREE THERAPY; VIRUS; INFECTION; PEGINTERFERON/RIBAVIRIN; COMBINATION; RESPONDERS; INHIBITOR; VARIANTS;
D O I：
10.1007/s40265-014-0279-4
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The combination of daclatasvir + asunaprevir [Daklinza (R) + Sunvepra (R) (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis. Daclatasvir + asunaprevir has received its first global approval in this indication in Japan. Daclatasvir + asunaprevir is the first all-oral, interferon- and ribavirin-free regimen for this indication. This article summarizes the milestones in the development of daclatasvir + asunaprevir leading to this first approval for the treatment of chronic HCV genotype 1 infections.
引用
收藏
页码：1559 / 1571
页数：13
相关论文
共 44 条
  • [1] [Anonymous], 61 ANN M AM ASS STUD
  • [2] Interferon free therapy with direct acting antivirals for HCV
    Asselah, Tarik
    Marcellin, Patrick
    [J]. LIVER INTERNATIONAL, 2013, 33 : 93 - 104
  • [3] Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
    Bifano, Marc
    Sevinsky, Heather
    Hwang, Carey
    Kandoussi, Hamza
    Jiang, Hao
    Grasela, Dennis
    Bertz, Richard
    [J]. ANTIVIRAL THERAPY, 2014, 19 (05) : 511 - 519
  • [4] Bristol-Myers Squibb Company, 2013, PHAS 3 CHIN GT 1B IN
  • [5] Bristol-Myers Squibb Company, 2011, 3 YEAR FOLL UP STUD
  • [6] Bristol-Myers Squibb Company, 2014, DAKL TABL TAV
  • [7] Bristol-Myers Squibb Company, 2014, SUNV CAPS AS
  • [8] Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
    Chae, Hee Bok
    Park, Seon Mee
    Youn, Sei Jin
    [J]. SCIENTIFIC WORLD JOURNAL, 2013,
  • [9] EXPOSURE-RESPONSE ANALYSES OF ASUNAPREVIR IN COMBINATION WITH DACLATASVIR ± PEGINTERFERON/RIBAVIRIN AMONG PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION: DOSE SELECTION FOR PHASE 3 CLINICAL TRIALS
    Chan, P.
    Tafoya, E.
    Eley, T.
    He, B.
    Mendez, P.
    Gardiner, D.
    Hughes, E.
    Schnittman, S.
    Bertz, R. J.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S328 - S329
  • [10] Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
    Chayama, Kazuaki
    Takahashi, Shoichi
    Toyota, Joji
    Karino, Yoshiyasu
    Ikeda, Kenji
    Ishikawa, Hiroki
    Watanabe, Hideaki
    McPhee, Fiona
    Hughes, Eric
    Kumada, Hiromitsu
    [J]. HEPATOLOGY, 2012, 55 (03) : 742 - 748
12345